Drug Trial Radar · NCT07261241
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
118
Planned (sponsor's estimate)
Start
Dec 31, 2026
Primary completion
Dec 31, 2030
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- New Approaches to Neuroblastoma Therapy ConsortiumAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United Therapeutics; Jubilant DraxImage Inc.
- First posted
- Dec 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vorinostat. Patients on Arm B will receive a single treatment course with 131I-MIBG and dinutuximab. Patients on Arm C will receive a single treatment course with 131I-MIBG with dinutuximab + vorinostat. After this course of treatment, we will check to see your response and then check to see how you are doing over time. All patients may choose to proceed to a second course of the same treatment if they and their physician feel healthy enough to do so. Approximately 118 patients will be receiving therapy on this trial.
Conditions
- Neuroblastoma
Interventions
Radiation: 131I-MIBGDrug
Patients will receive 131I-MIBG 18 mCi/kg (maximum dose 1200 mCi) on Day 1
DinutuximabDrug
Dinutuximab 17.5 mg/m2/day is given intravenously on Days 8-11 and 29-32 of therapy
VorinostatDrug
Vorinostat will be given on days 0-13 at a dose of 180 mg/m2/dose (maximum dose 400 mg).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Tumor Response After One Course of TherapyTime frame: 43-57 days from study day 1
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Children Hospital of Colorado
Aurora, Colorado
Children's Healthcare of Atlanta
Atlanta, Georgia
Children's Memorial Hospital - Chicago
Chicago, Illinois
Childrens Hospital Boston, Dana-Farber Cancer Institute.
Boston, Massachusetts
C.S Mott Children's Hospital
Ann Arbor, Michigan
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
University of Texas Southwestern
Dalls, Texas
Cook Children's Medical Center - Fort Worth
Fort Worth, Texas
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.